New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - metformin hydrochloride 1000mg;  ;   - coated tablet - 1000 mg - active: metformin hydrochloride 1000mg     excipient: magnesium stearate opadry clear oy-29020 povidone water - -treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. -metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents. - adjuvant therapy in insulin dependent diabetes especially if overweight.

New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - quetiapine fumarate 115.122mg equivalent to 100 mg quetiapine - film coated tablet - 100 mg - active: quetiapine fumarate 115.122mg equivalent to 100 mg quetiapine excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry yellow 03b82923 povidone purified talc sodium starch glycolate - acute and chronic psychoses, including schizophrenia.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - danazol 100mg - capsule - 100 mg - active: danazol 100mg excipient: colloidal silicon dioxide gelatin   iron oxide black   lactose lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate sodium starch glycolate tekprint black sw-9008 titanium dioxide   - endometriosis: danazol is indicated for use in the treatment of endometriosis amenable to hormonal management. menorrhagia: danazol is indicated for the short-term (up to 6 months) management of primary menorrhagia. fibrocystic disease of the breast: danazol is indicated for the treatment of fibrocystic disease of the breast in both pre- and post-menopausal women. hereditary angioedema: danazol is indicated for the prophylaxis of attacks of hereditary angioedema of a severe or life-threatening nature, in male and female patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - doxycycline hydrochloride 114mg (as docyclycine hyclate = doxycycline 100mg);   - tablet - 100 mg - active: doxycycline hydrochloride 114mg (as docyclycine hyclate = doxycycline 100mg)   excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry white y-1r-7000b

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 100mg - tablet - 100 mg - active: sodium valproate 100mg excipient: hydrated silica light kaolin magnesium stearate maize starch purified water - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - amisulpride 100mg;  ;  ; amisulpride 100mg - tablet - 100 mg - active: amisulpride 100mg     excipient: hydrated silica lactose monohydrate magnesium stearate methylcellulose potato starch active: amisulpride 100mg excipient: hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - sertraline hydrochloride 111.9mg ((form-i) equivalent to 100mg sertraline);  ;  ;   - film coated tablet - 100 mg - active: sertraline hydrochloride 111.9mg ((form-i) equivalent to 100mg sertraline)       excipient: calcium hydrogen phosphate hyprolose hypromellose macrogol 400 magnesium stearate microcrystalline cellulose polysorbate 80 purified water sodium starch glycolate titanium dioxide - arrow - sertraline is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) - transdermal patch - 100 mcg/24h - active: estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

New Zealand - English - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - estradiol 0.312 mg/cm² equivalent to 100 µg/24h;   - transdermal patch - 100 mcg/24h - active: estradiol 0.312 mg/cm² equivalent to 100 µg/24h   excipient: ethyl acetate ethyl oleate glyceryl monolaurate isopropyl myristate methanol polyethylene

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - irinotecan hydrochloride trihydrate 100mg; irinotecan hydrochloride trihydrate 100mg - concentrate for injection - 100 mg - active: irinotecan hydrochloride trihydrate 100mg excipient: lactic acid sodium hydroxide sorbitol water for injection active: irinotecan hydrochloride trihydrate 100mg excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan actavis is indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan actavis is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.